Special Issue "Clinical Advances of Human Papillomaviruses"
Deadline for manuscript submissions: closed (30 September 2014)
The human papillomavirus (HPV) is responsible for the majority of newly acquired sexually transmitted infections (STIs) in the United States (in the year 2013). HPV is also an essential carcinogen; it is increasingly implicated in association with cancers occurring at numerous sites of the body, including the oropharynx. The virus is well-known as the cause of nearly 100 percent of all cervical cancers. The significant health and economic burdens of disease continue to stimulate research on the virus, with special interest in decreasing disease transmissibility through vaccination and improvements in cancer screening. Recent screening advancements by national health organizations have guided physicians in the way they screen for cervical cancer with respect to starting and stopping age, frequency, and select groups for which the standard recommendations do not apply. Although there is not currently any specific treatment for the HPV infection, the diseases it causes are treatable. Two vaccines have been developed against HPV infection: the bivalent and quadrivalent vaccines approved in 2006 for use in women and the quadrivalent vaccine approved in 2009 for use in men (as well as women).
This Special Issue is composed of articles that reflect the latest developments of the human papillomaviruses, with additional focus on anticipated advances of the disease.
Prof. Dr. Stephen Tyring
Dr. Christopher Downing
Dr. Jacqueline Guidry
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- cervical cancer
- pap smear